We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Research of Biomarkers in Duchenne Muscular Dystrophy Patients (IBISD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01380964
First Posted: June 27, 2011
Last Update Posted: August 17, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Institute of Myology
Information provided by (Responsible Party):
Genethon
June 23, 2011
June 27, 2011
August 17, 2016
June 2011
December 2015   (Final data collection date for primary outcome measure)
IBiSD aims to identify and validate new and disease-specific biomarkers. [ Time Frame: End of study ]
This study will establish the relevance of urinary and blood biomarkers for the diagnosis, follow-up and assessment of treatment response in patients with DMD (IBiSD1, 2 and 4). IBiSD will also attempt to establish the seroprevalence to the different strains of AAV in patients with DMD (IBiSD3).
Not Provided
Complete list of historical versions of study NCT01380964 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Research of Biomarkers in Duchenne Muscular Dystrophy Patients
Research of Biomarkers for Disease Diagnosis, Disease Monitoring and Therapeutic Treatment Response in Duchenne Muscular Dystrophy Patients
The purpose of this study is to identify potential biomarkers for the diagnosis, disease progression assessment and response to treatment in patients with Duchenne Muscular Dystrophy.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
DNA, serum, t lymphocytes, urine
Probability Sample
patients with Duchenne Muscular Dystrophy controls (healthy or patients with a non-related disease)
Duchenne Muscular Dystrophy (DMD)
Not Provided
  • DMD patients
    DMD Patients
  • Control patients
    Control patients
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
220
December 2015
December 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • FOR PATIENTS:
  • Diagnosis of DMD confirmed by genetic testing
  • Age over 3 years
  • Weight over 15 kg
  • Informed consent signed
  • FOR CONTROLS:
  • Age over 3 years
  • Male gender
  • Weight over 15 kg
  • Subjects with national health insurance coverage
  • Informed consent signed
  • Nonacute or chronic muscular, allergic, infectious, endocrine or inflammatory disorder in the 3 weeks preceding inclusion

Exclusion Criteria:

  • FOR PATIENTS:
  • Concomitant chronic or acute muscular, endocrine, infectious, allergic or inflammatory disorder in the three weeks preceding the blood test
  • Intake of medicines other than angiotensin-converting enzyme inhibitors, beta blockers, dietary supplements, vitamins, alendronate and methylphenidate. Steroids (and medicines prescribed with them such as calcium supplements and proton pump inhibitors) will be discussed
  • Mental retardation or autism
  • Vaccination or treatment with immunoglobulins within the three months preceding inclusion
  • FOR CONTROLS:
  • Concomitant chronic or acute muscular, neurological (including mental retardation and autism), infectious or inflammatory disorder in the three weeks preceding the blood test
  • Vaccination or treatment with immunoglobulins within the three months preceding inclusion
Sexes Eligible for Study: Male
3 Years to 20 Years   (Child, Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT01380964
GEE006.10
No
Not Provided
Not Provided
Genethon
Genethon
Institute of Myology
Principal Investigator: Laurent SERVAIS, MD Myology Institute
Genethon
August 2016